Method for treatment of generalized tics disease
FIELD: medicine, psychiatry, neurology.
SUBSTANCE: method involves carrying out pharmacotherapeutic treatment for 20 days. Method involves treatment with mexidolum in the dose 150-200 mg per 24 h by intravenous drop route, diazepam in the dose 15-20 mg per 24 h by intramuscular route, immune correcting drug thymogenum in the dose 1 ml of 0.01% solution by intramuscular route, once per 24 h for the first 10 days and then five injections every other day by intramuscular route. Hyperbaric oxygenation under excessive pressure 0.8-1 atm at the rate compression and decompression 0.1 atm per a minute, isopression period for 40 min, 2 times per 24 h, is carried out with pharmacotherapy simultaneously. Invention provides rapid and stable reducing the main psychopathological symptoms: simple and complex motive tics and vocalism based on nonspecific complex normalizing effect on neurohomeostasis.
EFFECT: enhanced and valuable method of disease treatment.
The invention relates to medicine, namely to psychiatry, and can be used in the treatment of patients with generalized disease ticks.
The disease is generalized ticks combines different kinds of ticks, on the one hand, and speech disturbances. Usually, therapy of this disease is limited to the use of antipsychotics with a symptomatic effect and cause a number of side effects (Buyanov MM System neuropsychiatric disorders in children and adolescents. A guide for physicians and speech therapists. Moscow, 2004). Clinical efficacy of haloperidol, a typical representative of this group, happy doubtful, because on the background of therapy with this drug was slightly reduced the severity of some symptoms, but overall regression was not observed. The duration of treatment is limited unwanted effects.
With this method of treatment is not considered the main pathogenetic mechanisms of disease: the neuroendocrine and immune dysfunction, ancelina hypoxia, impairment of protein, lipid, water and electrolyte exchange.
The technical result is rapid and complete reduction of major psychopathological symptoms: simple and complex motor tics and vocalisms due to nonspecific effects on naregamia the pelvis.
The invention consists in that within 20 days of conducting pharmacotherapy Mexidol in a dose of 150-200 mg per day intravenously, diazepam at a dose of 15-20 mg / day intramuscularly, immunocorrector timagenes 0,01% solution 1 ml intramuscularly 1 time per day for first 10 days, and then injection a day five injections. Simultaneously with pharmacotherapy within 20 days of conducting hyperbaric oxygenation pressure of 0.8 to 1 ATM at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress 40 minutes, 2 times a day.
The method is as follows. From the first day of treatment, patients are assigned Mexidol intravenously in a daily dose of 150-200 mg, diazepam intramuscularly in a dose of 15-20 mg per day. Drugs administered for 20 days. Immunocorrector timogen 0.01% per 1 ml intramuscularly 1 time per day administered during the first 10 days daily, and then injection a day five injections. At the same time within 20 days patients spend hyperbaric oxygenation in single chambers BLX-3-01 (Scientific-production Association "LAD", Russia) with a gauge pressure of 0.8-1.0 atmosphere at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress is 40 minutes. Sessions of hyperbaric oxygenation is carried out 2 times a day.
Clinical at the er. Patient P., 17 years old (case history No. 2736), entered in the Mordovian Republican psychiatric hospital of the city of Saransk 06.10.2005, in the direction of a psychiatrist, diagnosed with generalized Disease ticks. History: onset at age 6, when first appeared simple compulsive movements of the head, neck, shoulders, then musculoskeletal disorders were capturing the upper and lower limbs. Because of the emergence of complex motor tics - squats, jumping, touching others and vocalisms in the form of shouting certain words, phrases, Lal, - the child has become marginalized: they could not eat, to study in school. This clinic were followed for 11 years, against the background of repeated inpatient and outpatient treatment with neuroleptics.
Mental status at admission. Outwardly neat. Is oriented correctly in all views. During the conversation takes many simple and complex involuntary movements (tics). Squats and jumping on the spot, makes frequent blink movement, spits, nods, pumping its arms, touches others. Musculoskeletal disorders are accompanied by voice disorders in the form of barking, shouting some words. Because of the pronounced TIC seizures the patient is unable to hold a spoon, ISAT, tearing the paper. Due to hyperactivity with attention deficit expressed frustration education was conducted at home.
During the examination. General analysis of blood from 06.10.2005,: hemoglobin 129 g/l, ESR - 5 mm/h, the total number of leukocytes - 5,4×109/l, eosinophils - 5%, stab neutrophils - 6%, segmented neutrophils - 48%, lymphocytes - 38%, monocytes - 3%. Urinalysis - without a pathology.
The immunological dated 07.10.2005, T-lymphocytes and 68%, lymphocytes - 4%, immunoglobulin M - 56 mg %, immunoglobulin G - 670 mg %, immunoglobulin a - 42 mg %, the activity of neutrophil phagocytosis - 40%, T-helpers - 36%, T-suppressors - 0%, circulating immune complexes, large - $ 7, circulating immune complexes medium - $ 25, circulating immune complexes of small - $ 143, adhesion of neutrophils to 9%, nst-test - 2%index activation of neutrophils 0,07 USD, the load index is 6.8 cu, immunoregulatory index - 36. Conclusion: Immunopathological condition. Deficiency of humoral immunity (hypoinsulinemia class a and G), the weakening of the functional activity of neutrophils, inhibition of oxygendependent systems of neutrophils, the imbalance of T-subpopulations, increasing circulating immune complexes of different molecular weight, reduce tensions functioning of the immune system.
Hormonal status from 07.10.2005,: ti is eutrophy hormone - 0,13 IU-IU/ml, T4free - 8,35 pmol/l, antibodies to thyroglobulin is not found, the cortisol - 300,34 nmol/L.
Blood biochemistry. The increase of total lipids, total cholesterol, β-LDL, atherogenic index, increasing the concentration of malondialdehyde activity of aminotransferases in the blood plasma, the decrease in the concentration of potassium ions without compensatory growth in the concentration of sodium.
Diagnosis: the Disease is generalized ticks.
1. Sol. Mexidoli 5% - 3 ml (150 mg)
Sol. Natrii Chloridi 0,9% - 400 ml
Intravenous drip 2 times a day for 20 days.
2. Sol. Diazepami 0,5% - 3 ml (15 mg)
Intramuscular injection, 2 times a day for 20 days
3. Sol. Thymogeni 0,01% - 1 ml
Intramuscularly 1 time per day for 10 days, then every other day number 5.
4. Hyperbaric oxygenation with a gauge pressure of 0.8-1.0 atmospheres, at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress - 40 minutes, 2 times a day for 20 days.
On a background of treatment:
Positive dynamics was observed with 5 days of therapy, when some degenerate complex involuntary movements - squats, jumping from complex ticks preserved only touching others, simple tics and vocalism remained. To 10, and more for up to 15 days of treatment decreased the frequency of blink movements, spitting, to vcov head. Voice disorders in the form of barking, shouting some words are rare (2-3 times daily). Twitching hands became less pronounced, allowing the patient to independently take liquid foods and do not put, have the opportunity to write. By the 20th day of therapy vocalism, complex motor tics are degenerate completely. Simple musculoskeletal disorders in the form of turns of the head, shoulders twitching, tremors, involuntary movements of the limbs were extremely rare, mild and appeared only when excited. Reduction of motor and vocal tics had a positive impact on the emotional and volitional spheres of mental activity of the patient. The patient began to actively communicate with others, to build a real future plans.
During the examination. General analysis of blood from 27.10.2005 St,: hemoglobin - 135 g/l, ESR - 4 mm/h, the total number of leukocytes - 5,7×109/l, eosinophils - 3%, stab neutrophils - 2%, segmented neutrophils - 54%, lymphocytes - 38%, monocytes - 3%. Urinalysis - without a pathology.
The immunological from 27.10.2005 St, T-lymphocytes - 70%, lymphocytes 10%, the immunoglobulin class M - 70 mg %, immunoglobulin G -1000 mg %, immunoglobulin A - 105 mg %, the activity of neutrophil phagocytosis - 62%, T-helpers - 54%, T-suppressor - 12%of circulating immune complexes large - 0$, circulate the s immune complexes medium - 10 USD, circulating immune complexes of small - $ 52, adhesion of neutrophils to 45%, nst-test - 10%, the index of the activation of neutrophils to 0.15 USD, the load index is 2.1 cu, immunoregulatory index of 4.2. Conclusion: In comparison with immunological dated 07.10.2005, there is a positive trend: normalized number of immunoglobulin G, recovered the functional activity of neutrophils, activated oxygendependent system of neutrophils, decreased circulating immune complexes, system metrics - load index and immunoregulatory index correspond to the norm. Still hypoinsulinemia class And, despite considerable improvement in this index.
Hormonal status from 27.10.2005 St,: thyroid-stimulating hormone - 2,14 IU-IU/ml, T4free - 18,35 pmol/l, antibodies to thyroglobulin is not found, the cortisol - 550,34 nmol/L.
Blood biochemistry. Normalization of metabolic parameters is parallel to the major reduction of psychopathological symptoms. Normalized indicators electrolyte metabolism, possibly due to increased oxidative phosphorylation in mitochondria and providing calcium pumps required for operation of metabolic energy. Normal amount of albumin in the plasma, which helps to prevent possible fluid overload CL is current and prevents the destruction of mitochondria and other cellular structures.
28.10.05, the patient was discharged.
Mental state at the time of discharge. Outwardly neat. Is oriented correctly in all views. Complex involuntary movements and vocalisms not observed. During the conversation makes a single rare twitching head, hands. The patient writes, involuntary movements during eating is not observed.
The effect of the treatment is positive. Consult 3 months.
30.01.2006, during examination: impulsive twitching of the muscles of the shoulder girdle, arms - not observed. Within 3 months of complex motor tics and vocalism was not renewed. During the day are sporadic simple tick in the form of head turns, nods. The child was adapted in school, increased attention span.
Thus, in this clinical example, through the use of regimens with the inclusion of an antioxidant, anxiolytic, immunocorrector and hyperbaric oxygen therapy has achieved the expressed clinical effect and to obtain the stable and long-term remission.
The combination of pathogenic action allows for an effective and safe therapy of generalized disease ticks.
Method for the treatment of generalized disease ticks, namely, that within 20 days of conducting the pharmacotherapy of mexy is I at a dose of 150-200 mg / day intravenous drip, diazepam at a dose of 15-20 mg / day intramuscularly, immunocorrector timagenes with 0.01%solution of 1 ml intramuscularly 1 time per day for first 10 days, and then injection a day five injections, along with pharmacotherapy within 20 days of conducting hyperbaric oxygenation pressure of 0.8 to 1 ATM at a speed of compression and decompression of 0.1 atmospheres per minute, the period of isopress 40 min, 2 times per day.
FIELD: organic chemistry, pharmaceuticals.
SUBSTANCE: invention relates to new chemical compound of general formula I , or salts, or hydrates thereof. In formula I R1 represents group of formula -G1-R1a (wherein G1 represents single bond, oxygen, sulfur; R1a represents C1-C10-alkyl optionally substituted with halogen or C3-C8-cycloalkyl); R2, R3 and R4 are independently hydrogen or -G20-R20 (wherein G20 represents single bond, oxygen, sulfur, sulfinyl or sulfonyl; R20 represents C1-C6-alkyl optionally substituted with 1-3 halogen atoms or C3-C8-cycloalkyl); R5 and R6 are independently -X5-X6-X7 group (meanings of X5, X6 and X7 are as defined in specification) or R3 and R4 may together form pyrrol ring optionally substituted with C1-C6-alkyl; Ar represents phenyl, 1,3-benzodioxolyl, naphthyl, pyridyl, optionally substituted with 1-3 substituents (as defined in specification) Compounds of formula I has antagonistic activity in relates to receptors of corticotrophin releasing factor (CRF). Also disclosed are compounds, characterized by preferable structures, pharmaceutical compositions, using such compounds, intermediates for production thereof and method for treatment of various diseases mediated by CRF.
EFFECT: new compounds as antagonists of CRF receptors.
33 cl, 1 tbl, 316 ex
SUBSTANCE: on the 5th-7th d of alcohol refusal in addition to the complex of conventional therapy of post-abstinent sates it is necessary to prescribe halavit at the dosage of 100 mg/d for 10 d. The innovation suggested provides increased reducing astenic symptomatics in the present group of patients due to complex impact of halavit that includes immunomodeling, antioxidant action, increased resistance of erythrocytes to ethanol-induced hemolysis and prevention of tissue hypoxia.
EFFECT: higher efficiency of therapy.
1 ex, 2 tbl
SUBSTANCE: invention describes a percutaneous or permucous medicinal formulation used in treatment of nicotine dependence or elimination from the smoking habit. Proposed medicinal formulation comprises nicotine, nicotinic salt, a derivative of nicotine or substance enhancing effect of nicotine in combination with at least one additional substance effecting on the central nervous system. Oral dosing an additional substance effecting on the central nervous system excludes adverse effects and providing a simple and safety intake of drug for patients.
EFFECT: improved and valuable properties of formulation.
FIELD: organic chemistry, medicine, clinical pharmacology, pharmacy.
SUBSTANCE: invention relates to using a compound chosen from a group consisting of compound of the formula (I) and the formula (II) , an enantiomer chosen from a group consisting of compounds of the formula (I) and the formula (II), or mixture of enantiomers wherein one of an enantiomer prevails chosen from a group consisting of compounds of the formula (I) and the formula (II) used for manufacturing a pharmaceutical composition used in prophylaxis or treatment of the anxiety disorder. One of enantiomers can prevail in the composition and chosen from a group consisting of compounds of the formula (I) and the formula (II) with their content about 90%, 98% or above. Pharmaceutical compositions are designated for using in broad spectrum of anxiety disorders of different genesis.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
SUBSTANCE: method involves using dipeptidyl peptidase IV (DP IV or CD 26) or DP IV-like enzyme for producing drug for treating stress or anxiety cases. Inhibitors are usable in combination with neuropeptides Y. The inhibitors are transported in physiologically compatible carriers. The inhibitors are also produced as prodrugs.
EFFECT: enhanced effectiveness of treatment.
6 cl, 11 dwg, 2 tbl
FIELD: veterinary medicine and veterinary pharmacology.
SUBSTANCE: invention relates to application of compounds combining properties of selective antagonists of dopamine D2 receptor and agonists of 5-HT1A receptor, in particular (R)-(-)-2-[5-(4-fluorophenyl)-3-piridylmethylaminomethyl]-chromane or pharmaceutically acceptable salts thereof, or N-(4'-fluoro-3-biphenylmethyl)-N-2-(3-cyanophenoxyethyl)-amine or pharmaceutically acceptable salts thereof. Said compounds are useful in veterinary medicine for treatment of self-directed traumatic disorders, associated with behavioral stress-factors, and/or compulsive disorders, associated with behavioral stress-factors, and/or anxiety, associated with behavioral stress-factors.
EFFECT: effective method for treatment and prophylaxis of disorders, associated with behavioral stress-factors.
6 cl, 3 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention describes derivatives of 4-phenylpyridine N-oxides of the general formula (I) and their pharmaceutically acceptable acid-additive salts wherein R means hydrogen atom, lower alkyl or halogen atom; R1 means hydrogen atom; R2 and R2' mean independently of one another hydrogen, halogen atom, trifluoromethyl group, (lower)-alkoxy-group; or R2 and R2' can mean in common the group -CH=CH-CH=CH- optionally substituted with one or two substitutes taken among lower alkyl or (lower)-alkoxy-group; R3 and R3' mean independently of one another hydrogen atom, lower alkyl; R4 and R4' mean independently of one another -(CH2)mOR6 or lower alkyl; or R4 and R4' form in common with N-atom to which they are bound substituted R5-cyclic tertiary amine representing pyrrolidine-1-yl, piperidine-1-yl, piperazine-1-yl, morpholine-4-yl or 1,1-dioxomorpholine-4-yl; R5 means hydrogen atom, hydroxyl, -COOR3, -N(R3)CO-lower alkyl or -C(O)R3; R6 means hydrogen atom, lower alkyl; X means -C(O)N(R6)-, -N(R6)C(O)-; n = 0, 1, 2, 3 or 4; m = 1, 2 or 3. Also, invention describes a medicinal agent comprising these compounds. Compounds can be used as drugs in treatment or prophylaxis of diseases associated with antagonists of NK-1 receptor.
EFFECT: valuable medicinal properties of agent.
6 cl, 32 ex
FIELD: veterinary science.
SUBSTANCE: the present innovation deals with applying biologically active substance of adaptogenic action as eracond at the dosage of 45-55 mg/kg body weight in the form of 10%-aqueous solution daily during three 3-d-long courses at 3-d-long interval. The innovation provides decreased negative impact of stress-factors upon animal body, upon immune state, especially.
EFFECT: higher efficiency of prophylaxis.
1 ex, 2 tbl
FIELD: veterinary science.
SUBSTANCE: for the purpose to decrease emotional strain, anxiety (phobia), soften both psychic and psychological state and fear in farm animals one should apply an aqueous (80 ± 5)%-α-propylene glycol solution being of efficient tranquilizing action to provide favourable adaptation aftereffect.
EFFECT: higher efficiency of application.
FIELD: organic chemistry, medicine, pharmacy, pharmacotherapy.
SUBSTANCE: method involves administration in mammal the effective dose of 6-hydroxy-8-[4[4-(2-pyrimidinyl)piperazinyl]butyl]-8-azaspiro[4,5]-7,9-dione or its pharmaceutically acceptable salt of acid addition or its hydrate. Method expands arsenal of medicinal agents used for suppression of fear sensation.
EFFECT: valuable properties of agent.
3 tbl, 6 dwg, 4 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention proposes using the compound (R/S)-(-/+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman or (S)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman or their salts for preparing a medicinal agent. This agent is used in treatment of extrapyramidal motor disorders, in particular, in treatment of unfavorable effects of anti-parkinsonic preparations and using (S)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman in combination with an anti-parkinsonic preparation for preparing the combined medicinal agent. Also, invention relates to a pharmaceutical composition for treatment of extrapyramidal disorders and a set of the same designation. Proposed compounds are able to prevent catalepsy caused by usual anti-dopaminergic preparations and they are strong agonists of 5-HT1A-receptors in combination with antagonism to dopamine D2-receptors and interaction with D3-receptors that provides positive effects on extrapyramidal system in treatment of dyskinesia.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
26 cl, 10 ex
SUBSTANCE: invention proposes a medicinal preparation for treatment of extrapyramidal disorders (Parkinson's disease, dyskinetic and choreic syndromes, in particular, Huntington chorea, dystonic syndromes, later dyskinesia, tremor, Gilles de la Tourette's disease, ballism, fatigue legs syndrome and Wilson's disease), and a pharmaceutical composition and a set for the same designation also. As a medicinal preparation invention proposes (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman or its physiologically acceptable salt known early as a combined selective antagonist of dopamine D2 receptors and antagonist of serotonin receptor of 1A subtype. These properties and high affinity to D3 receptor show favorable effect on extrapyramidal and motor systems. Pharmaceutical composition and set comprise (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman or its salt and a medicinal preparation against Parkinson's disease as active compounds. The compound (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman decreased extrapyramidal moving disorders caused by neuroleptics and enhanced their anti-parkinsonic effect, i. e. it shows property to diminish symptoms of Parkinson's disease and to enhance the general activity.
EFFECT: improved and valuable medicinal properties of compound and pharmaceutical composition.
26 cl, 10 ex
FIELD: medicine, therapeutic stomatology.
SUBSTANCE: one should apply special medicinal preparations immobilized upon gelatin-glycerin splin, the foundation of which is presented as 28.57% gelatin, 17.86% glycerin and 53.57% water. Moreover, during the first 3 d one should apply malavit thrice daily after breakfast, dinner and before nocturnal period. Then, during 3 d patients should apply medicinal splints with trental in the morning, and before nocturnal sleeping - those with thymogenum, at final stage of therapy for 3 d it is necessary to use splints with collargol in the morning and before nocturnal sleeping. The innovation enables to interrupt inflammatory process efficiently and short period of time due to high-degree releasing of medicinal substances at strong fixation of the splints applied.
EFFECT: higher efficiency of therapy.
2 cl, 1 ex
FIELD: medicine, dermatology.
SUBSTANCE: method involves administration of an immunomodulator polyoxidonium or immunofan. In the case of patients with accompanying digestive tract diseases and after removal of papillomas of number below 50 polyoxidonium is administrated by the following schedule: by one suppository for 5 days at a time and by one suppository every other day. In the case of patients with the larger process incidence and with chronic tonsillitis immunofan is administrated is administrated by the following schedule: by 1 ml every other day (5 doses) and then 1 time, twice per a week (5 doses), and then 1 time per a week (5 doses). After the basic treatment course with immunomodulators the infusion of herbal species with immunomodulating properties is administrated of the following composition p.p.: buckthorn bark 60.0; peppermint leaves, 20.0; dandelion roots, 20.0; fennel and parsley fruits, by 20.0. Two table spoons of mixture is poured with two glasses of boiling water, boiled for 5 min, infused for 1 h and taken in the dose two glasses in morning before eating for 20 days. Also, preparation "Aevit" is given in the dose two capsules per a day for 3 weeks and treatment of accompanying diseases is carried out also. Method provides effectiveness of treatment and prophylaxis of relapses of skin pappilomas based on the complex effect on the immune system by immunomodulating preparations in combination with vegetable immunostimulators that prolong their effect. Invention can be used in treatment of skin papillomas.
EFFECT: improved method for prophylaxis.
1 tbl, 2 ex
FIELD: medicine, oncology.
SUBSTANCE: invention relates to a method for treatment of malignant tumors. Method involves administration in a patient the chemotherapeutically active dose of antitumor platinum compound, foe example, cisplatin or carboplatin and erythropoietin or erythropoietin-like substance wherein the latter is administrated before administration of platinum compound or simultaneously with its. This method provides attaining the synergistic antitumor effect.
EFFECT: improved and valuable medicinal effect.
8 cl, 2 tbl, 2 dwg, 2 ex